دورية أكاديمية
Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models
| العنوان: | Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models |
|---|---|
| المؤلفون: | Lorenzo, Maria M., Marín-López, A., Chiem, Kevin, Jiménez-Cabello, Luis, Ullah, Irfan, Utrilla-Trigo, S., Calvo Pinilla, Eva María, Lorenzo, Gema, Moreno, Sandra, Ye, Chengjin, Park, Jun-Gyu, Matía, Alejandro, Brun Torres, Alejandro, Sánchez-Puig Eyre, Juana María, Nogales, Aitor, Mothes, Walther, Uchil, Pradeep D., Kumar, Priti, Ortego, Javier, Fikrig, Erol, Martínez-Sobrido, Luis, Blasco Lozano, Rafael |
| المساهمون: | Instituto de Salud Carlos III, Agencia Estatal de Investigación (España), European Commission, CSIC - Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), San Antonio Medical Foundation, Texas Biomedical Forum, Lorenzo, Maria M., Marín-López, A., Chiem, Kevin, Jiménez-Cabello, Luis, Utrilla-Trigo, S., Calvo Pinilla, Eva María, Lorenzo, Gema, Moreno, Sandra, Ye, Chengjin, Matía, Alejandro, Brun Torres, Alejandro, Sánchez-Puig Eyre, Juana María, Nogales, Aitor, Mothes, Walther, Uchil, Pradeep D., Kumar, Priti, Ortego, Javier, Fikrig, Erol, Martínez-Sobrido, Luis, Blasco Lozano, Rafael |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute |
| سنة النشر: | 2023 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | COVID-19, SARS-CoV-2, Immunization, Modified vaccinia virus Ankara, Poxvirus, Recombinant viral vectors, Vaccine |
| الوصف: | 24 Pág. ; The COVID-19 pandemic has underscored the importance of swift responses and the necessity of dependable technologies for vaccine development. Our team previously developed a fast cloning system for the modified vaccinia virus Ankara (MVA) vaccine platform. In this study, we reported on the construction and preclinical testing of a recombinant MVA vaccine obtained using this system. We obtained recombinant MVA expressing the unmodified full-length SARS-CoV-2 spike (S) protein containing the D614G amino-acid substitution (MVA-Sdg) and a version expressing a modified S protein containing amino-acid substitutions designed to stabilize the protein a in a pre-fusion conformation (MVA-Spf). S protein expressed by MVA-Sdg was found to be expressed and was correctly processed and transported to the cell surface, where it efficiently produced cell-cell fusion. Version Spf, however, was not proteolytically processed, and despite being transported to the plasma membrane, it failed to induce cell-cell fusion. We assessed both vaccine candidates in prime-boost regimens in the susceptible transgenic K18-human angiotensin-converting enzyme 2 (K18-hACE2) in mice and in golden Syrian hamsters. Robust immunity and protection from disease was induced with either vaccine in both animal models. Remarkably, the MVA-Spf vaccine candidate produced higher levels of antibodies, a stronger T cell response, and a higher degree of protection from challenge. In addition, the level of SARS-CoV-2 in the brain of MVA-Spf inoculated mice was decreased to undetectable levels. Those results add to our current experience and range of vaccine vectors and technologies for developing a safe and effective COVID-19 vaccine. ; This research was funded by Instituto de Salud Carlos III, Fondo COVID-19 de proyectos de investigación sobre SARS-CoV-2 y la enfermedad COVID-19 grant COV20/00901, and grant PID2021-128466OR-I00 funded by funded by MCIN/AEI/10.13039/501100011033 as part of Plan Estatal de Investigación Científica, Desarrollo e Innovación. ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2076-393X |
| العلاقة: | #PLACEHOLDER_PARENT_METADATA_VALUE#; info:eu-repo/grantAgreement/AEI//PID2021-128466OR-I00; Centro de Investigación en Sanidad Animal (CISA); Publisher's version; https://doi.org/10.3390/vaccines11051006Test; Sí; Vaccines 11(5): e1006 (2023); http://hdl.handle.net/10261/331347Test; 2-s2.0-85160305767; https://api.elsevier.com/content/abstract/scopus_id/85160305767Test |
| DOI: | 10.3390/vaccines11051006 |
| الإتاحة: | https://doi.org/10.3390/vaccines11051006Test http://hdl.handle.net/10261/331347Test https://api.elsevier.com/content/abstract/scopus_id/85160305767Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.52BE3D3B |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 2076393X |
|---|---|
| DOI: | 10.3390/vaccines11051006 |